



慧智基因股份有限公司

SOFIVA GENOMICS CO., LTD.



創辦人蘇怡寧醫師從臺大醫院到2012年成立慧智基因，為理想逐步踏實地建構起整合母胎兒醫學、基因遺傳醫學、生殖醫學與臨床醫學的新世代基因診斷營運平臺，以專業和熱忱提供全方位服務，照護大眾的健康。

慧智來自基因科學的生命之樹

十多年前，蘇怡寧醫生遇到一名曾產下裘馨氏肌肉萎縮症寶寶的媽媽多次求診，由於這是一種性聯遺傳隱性疾病，讓她不斷被夫家指責，感到無助又痛苦。因此，當她再婚步入新家庭，面對生小孩時，心中只有深深的悲傷與恐懼，加上當時基因醫學技術還未臻成熟，蘇醫師也只能陪著這位媽媽焦慮。幸好上天眷顧，懷胎女嬰並沒有遺傳到疾病。

緣此蘇醫師決心鑽研基因診斷領域，要讓臺灣的基因醫學技術與全球同步。先在

臺大醫院成立分子遺傳實驗室，憑著滿腔熱誠與使命，研發技術、發表臨床報告，經過十年的努力才慢慢發展茁壯。但仍受限於國內醫療環境，許多理想窒礙難行。

於是，集結號召臺灣母胎兒醫學領域、基因遺傳醫學領域與臨床醫學領域之權威醫師與專家顧問，成立慧智基因，建立新世代基因診斷營運平臺，以專業和熱忱提供全方位服務，對遺傳疾病病患、家屬提供更多的幫助與照護，讓所有爸媽安心地迎接新生命。

持續超越自我 拓展海外市場

洪加政總經理在臺灣大學醫學工程所與基因體暨蛋白體醫學研究所就讀碩博士時，成為蘇怡寧醫師的學生，洪總經理有豐富的生物醫學工程、基因和遺傳疾病篩檢技術研發、基因和遺傳疾病檢測平臺建構經驗，學術知識與技術能力雄



左：蘇怡寧 董事長暨 執行長

右：洪加政 總經理

Left : CEO & Managing Chairman Yi Ning, Su

Right : General Manager Dr.Chia Cheng, Heng

負責人：蘇怡寧

地址：100台北市中正區寶慶路27號

電話：02-23826615

傳真：02-23826617

推薦單位：中小企業信用保證基金

營業項目：母胎兒檢測、癌症基因檢測、生殖醫學
檢測

產品名稱：次世代定序胚胎著床前染色體篩檢、慧
智非侵產前染色體篩檢、慧智全方位複
合式晶片檢測、慧智帶因篩檢、慧智癌
篩檢、慧智癌監控

Owner : Yi Ning, Su

Address : No. 27, Baoqing Rd., Zhongzheng Dist.,
Taipei City 100, Taiwan

Tel : +886-2-23826615

Fax : +886-2-23826617

Recommended by : Small and Medium Enterprise
Credit Guarantee Fund of Taiwan

Business Items : Prenatal,Cancer,Reproductive
Screening Test

Products : NGS-based Preimplantation Genetic
Screening、SOFIVA NIPS (Non-Invasive Prenatal
Screening)、SOFIVA Array、SOFIVA Carrier
Scan、SOFIVA Cancer Scan、SOFIVA Cancer
Monitor

厚。洪總經理全力投入慧智基因，擔任發展策略、技術開發與營運管理的領航者，帶領慧智迎向基因醫學新藍海。

慧智居於基因醫學發展的領導地位，擁有最新儀器設備、核心技術與研發優勢，以國際型實驗室規格與專業，與醫療界、學術界頂尖專家與實驗單位緊密交流合作，包含臺灣優秀的醫學中心與基因實驗團隊，更跨越國際與illumina®、Roche進行多方面的合作與臨床分析資源共享，務求提供客戶最先進、最優質的服務。目前已與美國、日本、香港、新加坡、馬來西亞、泰國、印尼、越南、菲律賓等國家建立長期合作關係，未來將更積極地拓展業務範圍與服務地區，為更多客戶提供高品質的基因診斷與遺傳諮詢服務。

榮耀獲獎肯定 創新屢獲佳績

慧智專注每個細節、追求完美品質，用心經營基因診斷服務。主動做好內控管理。在精益求精之餘，透過國際驗證單位，為實驗流程與品質進行專業評核與認證；也積極參與贏得獎項，由公正單位為消費者確保創新研發的產品與服務，具備高質量的市場優勢；同時更善盡企業公民責任，成為政府單位合作機構，為遺傳性疾病、罕見疾病患者提供優質服務。



蘇怡寧董事長榮獲青創楷模獎

Chairman Mr. Yi Ning Su received the Award of Model of
Entrepreneurs



Dr. Yi-Ning Su is committed to advancing research and clinical application in the field of maternal-fetal medicine (MFM). He is an internationally renowned scholar, gynecologist, and clinical geneticist specializing in prenatal diagnosis and genetic testing. His vision for SOFIVA is to build a world-class, comprehensive genetic testing facility that benefits and contributes to improving public health.

Keep exploring the Tree of Life

More than a decade ago, Dr. Yi-Ning Su treated a woman who had given birth to a baby with Duchenne muscular dystrophy (DMD). She felt helpless and distressed, as her husband's family blamed her for being a carrier of the X-linked recessive genetic disorder. When she married into a new family, she was terrified at the thought of falling pregnant. At the time, medical genetic technology was relatively immature, and Dr Su could only acknowledge and share her concerns. Fortunately, the woman gave birth to a healthy girl who did not have DMD.

Dr. Su decided to devote himself to genetic diagnostics and advance genetic technology in Taiwan. He founded the Laboratory of Molecular Genetic Diagnostics at National Taiwan University Hospital and worked hard to research and



1. 蘇怡寧執行長、洪加政總經理與技術團隊
Dr. Yi-Ning Su, CEO & Managing Director
Dr. Chia-Cheng Hung, General Manager and technology team

2. 次世代定序室 Next-Generation Sequencing(NGS)

3. 晶片分析 Microarray Aiagnosis



慧智華麗復古派對 The Party of SOFIVA Genomics



慧智基因泰國子公司 SOFIVA GENOMICS Bangkok Co., Ltd



員工旅遊 Company trip

develop techniques, and publish clinical studies. After a decade of effort, he had achieved some robust outcomes. However, the limitations of the local healthcare environment made it difficult to implement many of his ideas.

Dr. Su recruited a team of authoritative experts and medical professionals in the fields of maternal-fetal medicine, medical genetics, and clinical medicine, and founded SOFIVA GENOMICS Co. Ltd. Our team of passionate professionals provides effective genetic testing, as well as advisory and support services, to expectant parents, patients with genetic disorders, and their families.

Constant Pursuit of Excellence

SOFIVA has long been a leader in the field of genetic medicine, and employs the most up to date equipment and core technologies, as well as superior R&D capabilities. Our elite team of

experts in maternal-fetal, genetic, reproductive, and clinical medicine provide a world-class suite of testing services that are professional, safe, and of the highest quality.

Awards and Certifications

At SOFIVA, we are attentive to every detail as we strive to perfect the quality of our genetic diagnostic services. We have established rigorous internal systems for quality control and continuous improvement. In addition, our lab processes and quality criteria have been audited and certified by international bodies. The awards we have won speak to the safety and quality of our innovative products and services. We are also committed to fulfilling our corporate social responsibility by partnering with the government to provide medical services to patients with genetic and rare diseases.



公司開幕親子日
Company Opening & Family Day



1. 泰國基因醫學實驗室 Medical Laboratory
2. DNA萃取 DNA Extraction
3. 洪加政總經理與同仁會議
Dr. Chia-Cheng Hung, General Manager
has a meeting with the staff in Taiwan.

為臺灣醫師首創基因檢測公司，與國內超過400間醫療院所合作，是臺灣基因檢測領導品牌。透過EIP整合，將公司內部資訊快速整合，讓員工與客戶得以快速獲得相關訊息。擁有國內提供檢測服務最完整的實驗室，核心競爭力為具有優秀人才和良好儀器設備，獨創一站式服務，建立遺傳疾病資料庫與診斷平台，提供所需者全方面服務，在母胎兒與癌症基因檢測具有相當市占率，企業永續經營無虞。

As Taiwan's first genetic testing company, the company works with over 400 medical institutions locally, making it the leading genetic testing brand in Taiwan. Through EIP integration, the internal company information can be integrated quickly, enabling employees and customers to promptly receive relevant information. Equipped with the most complete laboratory in the country providing testing services, the company's core competitiveness lies in its excellent talents and fine apparatuses. With the self-developed one-stop services, genetic disease databases, and diagnostic platforms, the company provides all-rounded services to those in need and takes up a considerable market share in fetus and cancer genetic testing, thereby ensuring management sustainability.